Physician profile
Ariol Labrada
NPI 1568621225
$5,874.33
in general payments reported to CMS, 2019-2025
45 companies · $2,173 in 2025
The $2,173 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $32.22 · 2021: $222 · 2022: $370 · 2023: $1,144 · 2024: $1,793 · 2025: $2,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,093 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,093.29 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $833.94 | 2024-2025 | |
| Ucb, INC. | $802.46 | 2021-2025 | Briviact, Fintepla, Rystiggo |
| Boston Scientific Corporation | $457.53 | 2019-2023 | Watchman Flx, Watchman Access System |
| Abbvie INC. | $424.62 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $365.54 | 2025 | Zeposia |
| Neurelis, INC. | $300.03 | 2023-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $243.34 | 2023-2024 | Qelbree |
| Pfizer INC. | $174.83 | 2024-2025 | |
| Csl Behring | $174.80 | 2024 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $173.67 | 2023-2025 | Fycompa |
| Sumitomo Pharma America, INC. | $165.52 | 2023-2024 | Aptiom |
| Argenx US, INC. | $143.64 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Cala Health, INC. | $132.10 | 2022 | |
| Abbott Laboratories | $130.48 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $121.40 | 2021-2024 | Wainua, Andexxa |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $115.32 | 2022-2025 | Ultomiris, Soliris |
| Otsuka America Pharmaceutical, INC. | $108.12 | 2024-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $101.91 | 2024-2025 | Rexulti |
| Sk Life Science, INC. | $56.91 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $56.64 | 2023-2024 | Austedo Xr, Austedo |
| Aucta Pharmaceuticals, INC. | $56.23 | 2025 | Motpoly Xr |
| Octapharma USA, INC. | $54.63 | 2024-2025 | Fibryga, Panzyga, Balfaxar |
| Allergan, INC. | $50.95 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $50.83 | 2023 | Ongentys, Ingrezza |
| Genentech USA, INC. | $45.67 | 2024-2025 | Ocrevus, Tnkase |
| Genzyme Corporation | $39.01 | 2023 | |
| Emd Serono, INC. | $37.37 | 2023 | Mavenclad |
| Amgen INC. | $36.30 | 2024-2025 | Uplizna |
| Horizon Therapeutics Plc | $34.97 | 2023 | Uplizna |
| Lilly USA, LLC | $34.85 | 2024 | |
| Lundbeck LLC | $31.95 | 2025 | Rexulti |
| Mallinckrodt Hospital Products INC. | $31.50 | 2025 | Acthar |
| Celgene Corporation | $29.96 | 2025 | Zeposia |
| Penumbra, INC. | $27.82 | 2025 | Smart Coil |
| Grifols USA, LLC | $26.12 | 2022 | |
| Mdd US Operations, LLC | $25.46 | 2024 | Gocovri |
| Biohaven Pharmaceutical Holding Company LTD. | $24.41 | 2022 | |
| Biogen, INC. | $22.91 | 2025 | Skyclarys |
| Ani Pharmaceuticals, INC. | $21.93 | 2024 | Purified Cortrophin Gel |
| Aprecia Pharmaceuticals, LLC | $21.28 | 2023 | Spritam |
| Avion Pharmaceuticals | $20.41 | 2023 | Dhivy |
| Ceribell, INC. | $20.00 | 2024 | Pocket Eeg Device |
| Merz Pharmaceuticals, LLC | $18.23 | 2023 | Xeomin |
| Acorda Therapeutics, INC | $16.28 | 2023 | Inbrija |
| Impel Pharmaceuticals INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariol Labrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.